REG - Oxford Biomedica PLC - PDMR Dealing

Oxford BioMedicaAnnouncement

21/05/2021 12:50

RNS Number : 4742Z
  
Oxford Biomedica PLC
  
21 May 2021
  
 

 
 
 
PDMR Dealing
 
Oxford, UK - 21 May 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed on 20 May 2021, that Dr. Kyriacos Mitrophanous, Chief Scientific Officer of the Group, exercised 25,000 LTIP (2014) options at nil cost, and sold all the resulting ordinary shares at 1096.9p per share. Following this transaction Dr. Kyriacos Mitrophanous continues to hold 147,476 options over ordinary shares.
 
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


Kyriacos Mitrophanous




2.


Reason for the notification




a)


Position/status


Chief Scientific Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Options over ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Exercise of options




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




Nil


25,000



 
 




e)


Aggregated information
-    Aggregate volume
 
-    Price
 
-    Aggregated total
 


 
25,000
 
 
Nil
 
Nil




f)


Date of the transaction


2021-05-19




g)


Place of the transaction


Outside a trading venue



 
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


Kyriacos Mitrophanous




2.


Reason for the notification




a)


Position/status


Chief Scientific Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Disposal




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




£10.97


 25,000



 
 




e)


Aggregated information
-    Aggregate volume
 
-    Price
 
-    Aggregated total
 


 
25,000
 
 
£10.9694
 
£274,235.00




f)


Date of the transaction


2021-05-19




g)


Place of the transaction


London Stock Exchange, Main Market (XLON)



 
-Ends-
 



For further information, please contact:


 




 
Oxford Biomedica plc:
Natalie Walter, Company Secretary


 
Tel: +44 (0)1865 783 000



 
 
About Oxford Biomedica
 
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHDKDBQDBKDQPB